Walter & Keenan Wealth Management LLC IN ADV lowered its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 2.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 42,082 shares of the company’s stock after selling 1,115 shares during the period. Johnson & Johnson accounts for 1.8% of Walter & Keenan Wealth Management LLC IN ADV’s portfolio, making the stock its 11th largest holding. Walter & Keenan Wealth Management LLC IN ADV’s holdings in Johnson & Johnson were worth $6,086,000 at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in JNJ. Vinva Investment Management Ltd grew its holdings in Johnson & Johnson by 6.8% during the third quarter. Vinva Investment Management Ltd now owns 111,448 shares of the company’s stock valued at $17,988,000 after purchasing an additional 7,110 shares during the last quarter. Financial Counselors Inc. grew its holdings in Johnson & Johnson by 5.3% during the third quarter. Financial Counselors Inc. now owns 185,093 shares of the company’s stock valued at $29,996,000 after purchasing an additional 9,309 shares during the last quarter. Oregon Pacific Wealth Management LLC acquired a new position in Johnson & Johnson during the fourth quarter valued at approximately $949,000. Meridian Investment Counsel Inc. grew its holdings in Johnson & Johnson by 19.6% during the third quarter. Meridian Investment Counsel Inc. now owns 22,629 shares of the company’s stock valued at $3,667,000 after purchasing an additional 3,710 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Johnson & Johnson by 0.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company’s stock valued at $2,858,543,000 after purchasing an additional 102,502 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.
Johnson & Johnson Stock Up 1.3 %
Shares of NYSE:JNJ opened at $157.24 on Friday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The company’s fifty day moving average is $147.58 and its 200-day moving average is $156.00. The company has a market capitalization of $378.58 billion, a PE ratio of 23.65, a P/E/G ratio of 2.46 and a beta of 0.52.
Johnson & Johnson Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.15%. Johnson & Johnson’s dividend payout ratio is presently 74.59%.
Insider Activity
In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on the company. Morgan Stanley reduced their price objective on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Wells Fargo & Company reduced their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Stifel Nicolaus reduced their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research report on Thursday, January 23rd. Citigroup reduced their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Finally, Leerink Partners reduced their price objective on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $170.67.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
See Also
- Five stocks we like better than Johnson & Johnson
- What is a Bond Market Holiday? How to Invest and Trade
- Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up
- 3 Warren Buffett Stocks to Buy Now
- Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
- Stock Dividend Cuts Happen Are You Ready?
- Buffett Buys More Occidental Petroleum—Sticking to His Playbook
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.